ArticleFrontiers in genetics2025
Biological characteristics and prognosis of acute myeloid leukemia in elderly patients.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Superior Efficacy and Deep Molecular Remission with Venetoclax Plus Hypomethylating Agent in Elderly Acute Myeloid Leukemia: A Real-World Comparative Cohort Study.Clinical pharmacology : advances and applications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Our study aimed to investigate the effects of chromosomal aberrations and genetic mutations of elderly individuals diagnosed with AML and determine its prognostic significance. Methods: We retrospectively collected data over nearly 7 years from our hospital, encompassing 90 cases of elderly AML patients. Baseline information of patients was gathered and followed up, and statistical analysis was conducted using SPSS 25.0. Results: Among the 90 elderly non-M3 AML patients, 56 (62.2%) exhibited multiple gene mutations, with 9 (10%) patients displaying five or more gene mutations. The incidence of Conclusion: Our findings suggest that elderly AML patients exhibit distinctive genetic profiles, and favorable prognosis genes do not seem to apply to elderly AML patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.